Debevoise Advises Allergan on Acquisition of Vitae Pharmaceuticals

14 September 2016

Debevoise & Plimpton LLP is advising Allergan plc (NYSE: AGN), a leading global pharmaceutical company, in its acquisition of Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company.

The companies have entered into a definitive agreement under which Allergan will acquire Vitae for $21.00 per share, in cash, for a total transaction value of approximately $639 million. The Boards of Directors of both companies have unanimously approved the transaction. Pending approvals, Allergan anticipates closing the transaction by the end of 2016.

The Debevoise team is led by partner Andrew L. Bab and includes partners Jeffrey P. Cunard, Gary M. Friedman and Jonathan F. Lewis and associates Matthew M. Delja, Samuel M. Duncan, Jennifer A. Gong, Michelle M. Hillenbrand, Sue Meng, Jennifer R. Roeske and Nicholas C.H. Roper.

Debevoise & Plimpton LLP is a premier law firm with market-leading practices, a global perspective and strong New York roots. We deliver effective solutions to our clients’ most important legal challenges, applying clear commercial judgment and a distinctively collaborative approach.